|Bid||14.73 x 1000|
|Ask||14.76 x 800|
|Day's range||14.55 - 14.99|
|52-week range||10.81 - 21.25|
|Beta (5Y monthly)||1.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Intercept Pharmaceuticals ( NASDAQ:ICPT ) Third Quarter 2022 Results Key Financial Results Revenue: US$77.6m (up 16...
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) were soaring 15.7% higher as of 12:02 p.m. ET on Tuesday. It also easily topped the average analysts' earnings estimate of $4.61 per share. Intercept's solid revenue growth was entirely due to higher Ocaliva sales.